|
|
Article: Gilead Sciences Announces VISTIDE available under Treatment IND program for patients with relapsing CMV retinitis.
- Article from:
- Business Wire
- Article date:
- September 5, 1995
CopyrightCOPYRIGHT 1995 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FOSTER CITY, Calif.--(HealthWire)--Sept. 5, 1995--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that VISTIDE(TM) (cidofovir intravenous) is now available under a Treatment Investigational New Drug (IND) Program for eligible patients with relapsing cytomegalovirus (CMV) retinitis. VISTIDE is an investigational therapeutic agent and will be made available free of charge in this program to patients who qualify and whose physicians register in the Treatment IND Program.
Under the Treatment IND Program, VISTIDE will be made more broadly available for the intravenous treatment of CMV retinitis in patients with AIDS whose disease has progressed despite treatment with ...